Log in

Intellia Therapeutics Price Target, Predictions & Analyst Ratings

+2.98 (+7.82 %)
(As of 12/2/2020 12:00 AM ET)
Today's Range
Now: $41.08
50-Day Range
MA: $29.44
52-Week Range
Now: $41.08
Volume3.31 million shs
Average Volume881,648 shs
Market Capitalization$2.43 billion
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

Intellia Therapeutics (NASDAQ:NTLA) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Intellia Therapeutics in the last 12 months. Their average twelve-month price target is $31.36, predicting that the stock has a possible downside of 23.67%. The high price target for NTLA is $57.50 and the low price target for NTLA is $20.00. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
NTLA Consensus Rating: BuyBuyBuyBuy
NTLA Consensus Rating Score: 2.642.602.502.50
NTLA Analyst Ratings: 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
NTLA Consensus Price Target: $31.36$31.36$28.90$26.21
NTLA Price Target Upside: 23.67% downside49.41% upside71.01% upside57.32% upside

Intellia Therapeutics (NASDAQ:NTLA) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Intellia Therapeutics (NASDAQ:NTLA) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/5/2020SVB LeerinkReiterated RatingOutperformMedium
10/27/2020TruistInitiated CoverageBuy$40.00 ➝ $40.00High
10/27/2020Summer StreetInitiated CoverageBuyHigh
10/19/2020Roth CapitalBoost Price TargetReduce ➝ Neutral$16.00 ➝ $26.00Low
10/14/2020Wells Fargo & CompanyInitiated CoverageOverweightMedium
9/30/2020OppenheimerReiterated RatingHoldHigh
9/18/2020The Goldman Sachs GroupInitiated CoverageBuy$33.00High
8/6/2020Chardan CapitalReiterated RatingBuyHigh
6/2/2020Credit Suisse GroupBoost Price TargetNeutral$19.00 ➝ $21.00High
6/1/2020WedbushBoost Price TargetNeutral$16.00 ➝ $20.00High
4/2/2020BTIG ResearchReiterated RatingBuy$22.00Low
11/1/2019Raymond JamesUpgradeMarket Perform ➝ Outperform$24.00High
7/8/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$23.00Medium
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
3/8/2018JMP SecuritiesInitiated CoverageMkt Outperform ➝ OutperformHigh
3/7/2018BarclaysBoost Price TargetOverweight ➝ Overweight$33.00 ➝ $46.00Medium
(Data available from 12/3/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.